Please check my math on shares sold from 4/2/18 thru
Please check my math on shares sold from 4/2/18 thru 5/9/18. I added up the total shares sold on the attached from 4kids and it came out to 6,690,500 shares sold. 4kids also mentions that the following volumes as of 5/9/18.
Volume (10 day Average) 229,990
Volume (90 day Average) 213,938
Per the 10Q IPIX sold 8M shares or an average of 285,714 shares/day through Aspire in that same period. I realize that none of us know the exact amount that Aspire sold on the open market but as mentioned by Sox, we know that Aspire has never filed a 13G indicating they own less than 5% or 7M shares of IPIX stock. The stock price dropped 30% from .51 to .36 during this period. So we know that Aspire held on to at least 1.3M shares (8M-6.69M) but represented a vast majority of the supply of shares available for sale during this period.
I am not stating that I don’t believe there are not criminal entities trying to cripple IPIX, as it is obvious that some entity with deep pockets has been funding the manipulation of the stock price going back to the orchestrated Mako/Rosen attack and has continued to date There are obvious shorting cabals but these guys are small players in the big picture and are again probably being paid off by an entity that either has competing drugs or is trying to buy IPIX assets cheaply. So to those that have argued whether it has been Aspire pressure on a thinly traded pre-revenue stock vs those that believe illegal activities including NSS, my position is that you are both right. It has been a layup for the short sellers UP TO THIS POINT. Science wins at the end and a partnership is a validation stamp and the end of dilution.
It has been painful to watch the share price spiral downward but there have been several “tells” that IPIX has communicated that tell me that:
- A B-OM deal is as good as done (negotiation stage) and will be finalized after the P results are known.
- P results have very good odds of being positive and there could be a P partnership very soon as well.
- Either of the above or possibly both will make the Aspire deal unnecessary going forward. (No more dilution)
- IPIX is exploring new facilities for corporate Headquarters. Over the next year company plans on increasing all areas of administration to include employees and facilities. If you were CEO why would you possibly do this unless you were positioning for major growth?
- IPIX has $2M in the bank ($1.3M cash plus $2M Aspire sales less $1M owed to CRO) and Leo has delayed any unnecessary expenditures.
- Evonik deal in place to produce B-OM packaging and probable B-UP foam etc. Would you sign a drug manufacturing contract if a deal wasn’t close?
- I haven’t even mentioned K which if successful could make IPIX a triple digit stock.
For a more complete list regarding the science check out posts by Drano, Sox, DaubersUP and others. The next few weeks should be exciting . GLTA longs,
15
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...
Continue Reading
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....
Continue Reading
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...
Continue Reading
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Investor Sentiment and Trends on SNAP Options Investors are showing an intriguing trend towards Snap (NASDAQ: SNAP) as they engage in notable options trading activities, indicating a potential shift in market dynamics that shouldn't be overlooked. Our examination of public options records reveals that significant players are backing a more optimistic outlook...
Continue Reading
StarKist and the Busch Family Kick Off NASCAR 2026 As the exhilarating NASCAR season launches, StarKist Co. is excited to announce its partnership with NASCAR champion Kyle Busch, wellness advocate Samantha Busch, and young racer Brexton Busch. Building upon a successful initial year, this collaboration emphasizes the importance of healthy, ready-to-eat protein options...
Continue Reading
Teva's Upcoming Presentations at Major Investor Conferences In a significant announcement, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is set to showcase its commitment to healthcare innovation. Richard Francis, the esteemed President and CEO of Teva, will represent the company at two prestigious investor conferences this September. Morgan Stanley Global Healthcare...
Continue Reading
Earth Animal's Heartwarming Holiday Initiative This holiday season, Earth Animal has kicked off a touching initiative called "Buy Joy to Gift Joy," which aims to make a difference in the lives of shelter dogs. In collaboration with Greater Good Charities, for every Pumpkin Spice or Holiday Feast No-Hide Chew sold, the company will donate one No-Hide® Strip to a shelter...
Continue Reading
Understanding the Sentencing of Stephen Hubbard A Moscow court has sentenced Stephen Hubbard, a 72-year-old American citizen, to six years and 10 months in prison for alleged involvement in combat against Russian forces alongside a Ukrainian unit. This case marks a significant moment, as it is the first instance of an American receiving imprisonment on 'mercenary' grounds...
Continue Reading